Pliant Therapeutics (PLRX) Price & Analysis

Compare

517 Followers

PLRX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.10 - $16.10

Previous CloseN/A

Volume34.91K

Average Volume (3M)1.53M

Market Cap

$103.74M

Enterprise Value-$162.82M

Total Cash (Recent Filing)$305.64M

Total Debt (Recent Filing)$60.17M

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Nov 11, 2025

EPS Estimate

-0.53

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.71

Shares Outstanding61,386,276

10 Day Avg. Volume903,032

30 Day Avg. Volume1,526,234

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap-1.57

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit261.77

Enterprise Value/Ebitda0.75

Forecast

1Y Price Target

$3.67

Price Target Upside118.45% Upside

Rating ConsensusHold

Number of Analyst Covering6

Bulls Say, Bears Say

Bulls Say

Cancer ResearchThe first-in-human Phase 1 study is now enrolling patients to the fourth of five cohorts, demonstrating PLN-101095's anti-tumor activity when combined with pembrolizumab in patients with immune checkpoint inhibitor-refractory advanced or metastatic solid tumors.

Financial PositionPLRX reported a cash position of $307M.

Oncology TrialsPliant reported that top-line data from the first three cohorts of the ongoing Phase I dose escalation trial of PLN-101095 in combination with pembrolizumab showed confirmed partial responses in solid tumors that are resistant.

Bears Say

Clinical TrialsPliant announced the discontinuation of the Phase IIb/III BEACON-IPF study for bexotegrast due to a higher rate of IPF-related adverse events observed in the bexo-treated groups of the study, compared to the placebo group.

Drug DevelopmentPLRX announced they are discontinuing development of bexotegrast in idiopathic pulmonary fibrosis.

Financial StrategyThe company recently announced a restructuring and workforce reduction to reduce cash burn.

Pliant Therapeutics News

Pliant Therapeutics price target lowered to $4 from $17 at Piper Sandler

Piper Sandler analyst Yasmeen Rahimi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $4 from $17...

13h ago

PLRX

Pliant Therapeutics reports Q2 EPS (71c), consensus (68c)

Reports Q2 cash, cash equivalents and short-term investments of $264.4M. The company has discontinued development of bexotegrast in...

1d ago

PLRX

Pliant Therapeutics Approves Key Proposals at Annual Meeting

Pliant Therapeutics ( ($PLRX) ) has issued an announcement. On April 9, 2025, Pliant Therapeutics held its Annual...

2M ago

PLRX

Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties

Analyst Edward Nash of Canaccord Genuity maintained a Hold rating on Pliant Therapeutics (PLRX – Research Report), retaining...

3M ago

PLRX

Cautious Hold Rating for Pliant Therapeutics Amidst Strategic Restructuring and Drug Development Uncertainties

Leerink Partners analyst Faisal Khurshid reiterated a Hold rating on Pliant Therapeutics (PLRX – Research Report) on May...

3M ago

PLRX

PLRX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Pliant Therapeutics, Inc. (PLRX) is scheduled to report 1st quarter earnings on 05/12/2025. Regarding Q1 estimates, Wall Street...

3M ago

PLRX

Pliant Therapeutics Reports Q1 2025 Financial Results

Pliant Therapeutics, Inc. ( ($PLRX) ) has released its Q1 earnings. Here is a breakdown of the information...

3M ago

PLRX

Pliant Therapeutics reports Q1 EPS (92c), consensus (62c)

“During the first quarter and over recent weeks, our teams have been working diligently to close out the...

3M ago

PLRX

Pliant Therapeutics reports Q1 EPS (92c), consensus (75c)

“During the first quarter and over recent weeks, our teams have been working diligently to close out the...

3M ago

PLRX

Pliant Therapeutics to reduce workforce by 45%

Pliant Therapeutics (PLRX) announced a strategic restructuring of its workforce and other cost saving actions to extend the...

3M ago

PLRX

Pliant Therapeutics Announces Major Workforce Reduction

Pliant Therapeutics ( ($PLRX) ) has issued an update. On May 1, 2025, Pliant Therapeutics announced a significant...

3M ago

PLRX

Hold Rating on Pliant Therapeutics Amid Uncertainty and Limited Data from Early-Stage Trials

Leerink Partners analyst Faisal Khurshid has reiterated their neutral stance on PLRX stock, giving a Hold rating yesterday....

5M ago

PLRX

Neutral Rating on Pliant Therapeutics Amid Early Promising Data and Uncertainties

H.C. Wainwright analyst Ed Arce has maintained their neutral stance on PLRX stock, giving a Hold rating on...

5M ago

PLRX

Pliant Therapeutics announces interim Phase 1 data from PLN-101095

Pliant Therapeutics (PLRX) announced data from the first three of five potential cohorts of its ongoing Phase 1...

5M ago

PLRX

PLRX FAQ

What was Pliant Therapeutics’s price range in the past 12 months?

Pliant Therapeutics lowest stock price was $1.10 and its highest was $16.10 in the past 12 months.

What is Pliant Therapeutics’s market cap?

Pliant Therapeutics’s market cap is $103.74M.

When is Pliant Therapeutics’s upcoming earnings report date?

Pliant Therapeutics’s upcoming earnings report date is Nov 11, 2025 which is in 94 days.

How were Pliant Therapeutics’s earnings last quarter?

Pliant Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.71 earnings per share for the quarter, missing the consensus estimate of -$0.677 by -$0.033.

Is Pliant Therapeutics overvalued?

According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pliant Therapeutics pay dividends?

Pliant Therapeutics does not currently pay dividends.

What is Pliant Therapeutics’s EPS estimate?

Pliant Therapeutics’s EPS estimate is -0.53.

How many shares outstanding does Pliant Therapeutics have?

Pliant Therapeutics has 61,386,276 shares outstanding.

What happened to Pliant Therapeutics’s price movement after its last earnings report?

Pliant Therapeutics reported an EPS of -$0.71 in its last earnings report, missing expectations of -$0.677. Following the earnings report the stock price went down -0.592%.

Which hedge fund is a major shareholder of Pliant Therapeutics?

Currently, no hedge funds are holding shares in PLRX

Pliant Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-63.22%

Trailing 12-Months

Asset Growth

-33.90%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pliant Therapeutics

Pliant Therapeutics (PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrotic diseases. The company operates in the biotechnology and pharmaceuticals sector, leveraging its proprietary platform to identify and advance small molecule therapeutics targeting key pathways in fibrosis, a process implicated in a wide array of serious diseases. Pliant's core products are centered on treating diseases like idiopathic pulmonary fibrosis and primary sclerosing cholangitis.

Pliant Therapeutics (PLRX) Earnings & Revenues

Historic Earnings Reports

PLRX Stock 12 Month Forecast

Average Price Target

$3.67

▲(118.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","4":"$4","8":"$8","12":"$12","16":"$16"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,4,8,12,16],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.58,1.7661538461538462,1.9523076923076923,2.1384615384615384,2.3246153846153845,2.5107692307692306,2.6969230769230768,2.8830769230769233,3.069230769230769,3.2553846153846155,3.441538461538461,3.6276923076923078,3.813846153846154,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.58,1.7407692307692308,1.9015384615384616,2.062307692307692,2.223076923076923,2.3838461538461537,2.5446153846153843,2.7053846153846153,2.8661538461538463,3.026923076923077,3.1876923076923074,3.3484615384615384,3.509230769230769,{"y":3.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.58,1.6892307692307693,1.7984615384615386,1.9076923076923078,2.016923076923077,2.126153846153846,2.2353846153846155,2.3446153846153845,2.453846153846154,2.563076923076923,2.672307692307692,2.7815384615384615,2.890769230769231,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.13,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.86,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.35,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.29,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.52,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.17,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.44,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.37,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.44,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.58,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >